Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: B.REVERE who wrote (4038)	7/8/1998 4:29:00 PM
From: Anthony Wong	Respond to of 9523

Some info about Vasomax in the Reuters article about Schering-Plough earnings. Not much of a threat to Viagra, it seems. Saks [Gruntal & Co analyst David Saks] said he expected Schering-Plough to file a New Drug Application this month with the U.S. Food and Drug Administration for Vasomax, a candidate impotence pill which would compete with Pfizer Inc.'s (PFE - news) blockbuster Viagra. Schering-Plough signed a deal late last year worth $57.5 million, exclusive of royalties, with Zonagen Inc. (ZONA - news) for worldwide rights to Vasomax, whose chemical name is phentolamine. CIBC Oppenheimer analyst Matthew Geller said he believed Vasomax, if approved by the FDA, would have 1999 sales of $31 million, growing to $106 million by the year 2000. biz.yahoo.com